Skip to main content
Top
Published in: Hepatology International 3/2013

01-07-2013 | Original Article

Downregulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with chronic hepatitis C

Authors: Li Kong, Kun Liu, Yu-Zhuo Zhang, Meng Jin, Bo-Rong Wu, Wei-Zhen Wang, Wei Li, Yue-Min Nan, Youhai H. Chen

Published in: Hepatology International | Issue 3/2013

Login to get access

Abstract

Purpose

Hepatitis C virus (HCV) infection causes chronic hepatitis in approximately 80 % of cases. Although it is well recognized that the immune system plays an important role in determining the outcomes of HCV infection, the underlying molecular mechanisms of persistent HCV infection and hepatic injury are incompletely understood. Tumor necrosis factor-α-induced protein 8-like 2 (TNFAIP8L2, TIPE2) is a newly identified negative regulator of innate and adaptive immunity. The goal of the present study is to investigate the potential role of TIPE2 in chronic hepatitis C (CHC) infection.

Methods

We used quantitative real-time reverse transcription polymerase chain reaction to examine the mRNA expression levels of TIPE2, Toll-like receptor (TLR) 2, and TLR4 in peripheral blood mononuclear cells from 60 CHC patients and 30 healthy controls.

Results

The TIPE2 mRNA expression was significantly downregulated, whereas that of TLR2 and TLR4 was upregulated in CHC patients compared with healthy controls. TIPE2 mRNA expression levels were negatively correlated with serum ALT, AST, and HCV RNA levels. TIPE2 mRNA expression was also negatively correlated with TLR2 and TLR4 mRNA levels in CHC patients. Moreover, TIPE2 mRNA expression was upregulated, whereas that of TLR2 and TLR4 was downregulated after treatment of patients with interferon-α and ribavirin.

Conclusions

These results indicate that HCV may promote chronic hepatitis by decreasing TIPE2 expression while enhancing TLR signaling.
Literature
1.
go back to reference Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20(1):1–16CrossRefPubMed Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20(1):1–16CrossRefPubMed
2.
go back to reference Isaguliants MG, Ozeretskovskaya NN. Host background factors contributing to hepatitis C virus clearance. Curr Pharm Biotechnol 2003;4(3):185–193CrossRefPubMed Isaguliants MG, Ozeretskovskaya NN. Host background factors contributing to hepatitis C virus clearance. Curr Pharm Biotechnol 2003;4(3):185–193CrossRefPubMed
3.
go back to reference Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X, Chen YH. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 2008;133(3):415–426CrossRefPubMed Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X, Chen YH. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 2008;133(3):415–426CrossRefPubMed
4.
go back to reference Lou Y, Liu S. The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. Mol Immunol 2011;49(1–2):4–7CrossRefPubMed Lou Y, Liu S. The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. Mol Immunol 2011;49(1–2):4–7CrossRefPubMed
5.
go back to reference Li D, Song L, Fan Y, Li X, Li Y, Chen J, Zhu F, Guo C, Shi Y, Zhang L. Down regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol 2009;133(3):422–427CrossRefPubMed Li D, Song L, Fan Y, Li X, Li Y, Chen J, Zhu F, Guo C, Shi Y, Zhang L. Down regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol 2009;133(3):422–427CrossRefPubMed
6.
go back to reference Zhang S, Zhang Y, Wei X, Zhen J, Wang Z, Li M, Miao W, Ding H, Du P, Zhang W, He M, Yi F. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta 2010;1802(11):1078–1086CrossRefPubMed Zhang S, Zhang Y, Wei X, Zhen J, Wang Z, Li M, Miao W, Ding H, Du P, Zhang W, He M, Yi F. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta 2010;1802(11):1078–1086CrossRefPubMed
7.
go back to reference Xi W, Hu Y, Liu Y, Zhang J, Wang L, Lou Y, Qu Z, Cui J, Zhang G, Liang X, Ma C, Gao C, Chen Y, Liu S. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammationin humans and mice. Mol Immunol 2011;48(9–10):1203–1208CrossRefPubMed Xi W, Hu Y, Liu Y, Zhang J, Wang L, Lou Y, Qu Z, Cui J, Zhang G, Liang X, Ma C, Gao C, Chen Y, Liu S. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammationin humans and mice. Mol Immunol 2011;48(9–10):1203–1208CrossRefPubMed
8.
go back to reference Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L, Chen YH. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic ras. Mol Cell 2012;45(5):610–618CrossRefPubMed Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L, Chen YH. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic ras. Mol Cell 2012;45(5):610–618CrossRefPubMed
9.
go back to reference Hepatotogy Branch, Infectious and Parasitology branch, Chinese Medical Association. Guideline of prevention and treatment for hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi 2004;38(3):210–215 Hepatotogy Branch, Infectious and Parasitology branch, Chinese Medical Association. Guideline of prevention and treatment for hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi 2004;38(3):210–215
10.
go back to reference Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological feature of hepatic injury and viral persistence. Hepatology 1999;30:595–601CrossRefPubMed Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological feature of hepatic injury and viral persistence. Hepatology 1999;30:595–601CrossRefPubMed
11.
12.
go back to reference Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008;134(3):812–822CrossRefPubMed Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008;134(3):812–822CrossRefPubMed
13.
go back to reference Mozer-Lisewska I, Dworacki G, Kaczmarek E, Sluzewski W, Kaczmarek M, Woźniak A, Zeromski J. Significance of alterations in PBMC immunophenotype of children with chronic viral hepatitis C—the role of dendritic cells. Scand J Immunol 2006;63(4):311–319CrossRefPubMed Mozer-Lisewska I, Dworacki G, Kaczmarek E, Sluzewski W, Kaczmarek M, Woźniak A, Zeromski J. Significance of alterations in PBMC immunophenotype of children with chronic viral hepatitis C—the role of dendritic cells. Scand J Immunol 2006;63(4):311–319CrossRefPubMed
14.
go back to reference Stamataki Z. Hepatitis C infection of B lymphocytes: more tools to address pending questions. Expert Rev Anti Infect Ther 2010;8(9):977–980CrossRefPubMed Stamataki Z. Hepatitis C infection of B lymphocytes: more tools to address pending questions. Expert Rev Anti Infect Ther 2010;8(9):977–980CrossRefPubMed
15.
go back to reference Panasiuk A, Parfieniuk A, Zak J, Flisiak R. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int 2010;30(3):472–478CrossRefPubMed Panasiuk A, Parfieniuk A, Zak J, Flisiak R. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int 2010;30(3):472–478CrossRefPubMed
16.
go back to reference Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis 2008;12(3):675–692CrossRefPubMed Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis 2008;12(3):675–692CrossRefPubMed
17.
go back to reference Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007;4(11):622–634CrossRefPubMed Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007;4(11):622–634CrossRefPubMed
18.
go back to reference Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A, Gerken G, Schlaak JF. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48(6):914–922CrossRefPubMed Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A, Gerken G, Schlaak JF. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48(6):914–922CrossRefPubMed
19.
go back to reference Imran M, Waheed Y, Manzoor S, Bilal M, Ashraf W, Ali M, Ashraf M. Interaction of hepatitis C virus proteins with pattern recognition receptors. Virol J 2012;9(1):126CrossRefPubMed Imran M, Waheed Y, Manzoor S, Bilal M, Ashraf W, Ali M, Ashraf M. Interaction of hepatitis C virus proteins with pattern recognition receptors. Virol J 2012;9(1):126CrossRefPubMed
20.
go back to reference Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, Tanaka T, Arai M, Fujiwara K, Saito K, Roger T, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 2011;204(5):793–801CrossRefPubMed Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, Tanaka T, Arai M, Fujiwara K, Saito K, Roger T, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 2011;204(5):793–801CrossRefPubMed
21.
go back to reference Caramalho I, Rodrigues-Duarte L, Perez A, Zelenay S, Penha-Gonçalves C, Demengeot J. Regulatory T cells contribute to diabetes protection in lipopolysaccharide-treated non-obese diabetic mice. Scand J Immunol 2011;74(6):585–595CrossRefPubMed Caramalho I, Rodrigues-Duarte L, Perez A, Zelenay S, Penha-Gonçalves C, Demengeot J. Regulatory T cells contribute to diabetes protection in lipopolysaccharide-treated non-obese diabetic mice. Scand J Immunol 2011;74(6):585–595CrossRefPubMed
22.
go back to reference Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, Li Y, Wang PZ, Bai XF. Circulating toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 2010;118(4):261–270CrossRefPubMed Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, Li Y, Wang PZ, Bai XF. Circulating toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 2010;118(4):261–270CrossRefPubMed
23.
go back to reference Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Oohashi T, Fukuzawa Y, Kakumu S. Expression of toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2007;22(10):1627–1632CrossRefPubMed Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Oohashi T, Fukuzawa Y, Kakumu S. Expression of toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2007;22(10):1627–1632CrossRefPubMed
24.
go back to reference Salem ML, El-Demellawy M, El-Azm AR. The potential use of toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cell Immunol 2010;262(2):96–104CrossRefPubMed Salem ML, El-Demellawy M, El-Azm AR. The potential use of toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cell Immunol 2010;262(2):96–104CrossRefPubMed
25.
go back to reference Yakushijin T, Kanto T, Inoue M, Oze T, Miyazaki M, Itose I, Miyatake H, Sakakibara M, Kuzushita N, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Reduced expression and functional impairment of toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. Hepatol Res 2006;34(3):156–162CrossRefPubMed Yakushijin T, Kanto T, Inoue M, Oze T, Miyazaki M, Itose I, Miyatake H, Sakakibara M, Kuzushita N, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Reduced expression and functional impairment of toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. Hepatol Res 2006;34(3):156–162CrossRefPubMed
26.
go back to reference Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17(9):2619–2627CrossRefPubMed Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17(9):2619–2627CrossRefPubMed
27.
go back to reference Poat B, Hazari S, Chandra PK, Gunduz F, Alvarez X, Balart LA, Garry RF, Dash S. Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication. Virol J 2010;7:265CrossRefPubMed Poat B, Hazari S, Chandra PK, Gunduz F, Alvarez X, Balart LA, Garry RF, Dash S. Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication. Virol J 2010;7:265CrossRefPubMed
28.
go back to reference Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y, Chen YH. TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol 2012;189(6):2768–2773CrossRefPubMed Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y, Chen YH. TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol 2012;189(6):2768–2773CrossRefPubMed
Metadata
Title
Downregulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with chronic hepatitis C
Authors
Li Kong
Kun Liu
Yu-Zhuo Zhang
Meng Jin
Bo-Rong Wu
Wei-Zhen Wang
Wei Li
Yue-Min Nan
Youhai H. Chen
Publication date
01-07-2013
Publisher
Springer India
Published in
Hepatology International / Issue 3/2013
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-013-9435-2

Other articles of this Issue 3/2013

Hepatology International 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.